Dechra Pharmaceuticals PLC Director/PDMR Shareholding (0190A)
September 24 2020 - 5:32AM
UK Regulatory
TIDMDPH
RNS Number : 0190A
Dechra Pharmaceuticals PLC
24 September 2020
24 September 2020
Dechra Pharmaceuticals PLC
Notification of Transactions by Persons Discharging Managerial
Responsibilities
On 24 September 2020, Dechra Pharmaceuticals PLC was notified by
a Director of the Company and Persons Discharging Managerial
Responsibilities that he had completed the sale of part of his
beneficial interest in Dechra.
Tony Griffin, Executive Director, has sold 4,400 ordinary shares
in the Company to satisfy long term personal financial planning
considerations and widen his investment portfolio. Following this
transaction, Tony Griffin will continue to retain a beneficial
holding of 70,650 ordinary shares which represents 0.065% of the
current issued share capital in the Company.
The Notification of Dealing Form set out below is provided in
accordance with Article 19.3 of MAR.
Notification of Dealing Form:
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Tony Griffin
------------------------------------- ----------------------------------
2. Reason for the notification
-------------------------------------------------------------------------
a) Position/status Director
------------------------------------- ----------------------------------
b) Initial notification/amendment Initial Notification
------------------------------------- ----------------------------------
3. Details of the Issuer
-------------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
------------------------------------- ----------------------------------
b) LEI code 213800J4UVB5OWG8VX82
------------------------------------- ----------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-------------------------------------------------------------------------
a) Description of the financial Ordinary Shares of 1 pence each
instrument ISIN: GB0009633180
Identification code
------------------------------------- ----------------------------------
b) Nature of the transaction Sale of Shares
------------------------------------- ----------------------------------
c) Price(s) and volumes(s) Price(s) Volume(s)
GBP 4,400
32.02609
------------------------------------- ------------------ --------------
d) Aggregated information
* Aggregate volume 4,400
GBP32.02609
GBP140,914.80
* Price
* Total
------------------------------------- ----------------------------------
e) Date of the transaction 23 September 2020
------------------------------------- ----------------------------------
f) Place of the transaction London Stock Exchange
------------------------------------- ----------------------------------
Enquiries:
Dechra Pharmaceuticals PLC
Ian Page, Chief Executive Office: +44 (0) 1606 814 730
Officer
Paul Sandland, Acting Chief Office: +44 (0) 1606 814 730
Financial Officer
e-mail: corporate.enquiries@dechra.com
TooleyStreet Communications
Ltd
Fiona Tooley, Director Office: +44 (0) 121 309 0099
e-mail: fiona@tooleystreet.com Mobile: +44 (0) 7785 703 523
---------------------------------------- ------------------------------
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and
related products business. Our expertise is in the development,
manufacture, and sales and marketing of high quality products
exclusively for veterinarians worldwide. Dechra's business is
unique as the majority of its products are used to treat medical
conditions for which there is no other effective solution or have a
clinical or dosing advantage over competitor products. For more
information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of
Dechra Pharmaceuticals PLC.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHKKQBNCBKKDCB
(END) Dow Jones Newswires
September 24, 2020 05:32 ET (09:32 GMT)
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From Apr 2023 to Apr 2024